TY - CONF
T1 - Atrial fibrillation patient health-related quality of life change over 6- and 12- months depending on the used oral anticoagulant type
AU - Apsīte, Ketija
AU - Eglītis, Toms Jānis
AU - Stoldere, Diāna
AU - Jubele, Kristīne
AU - Ivaščenko, Tarass
AU - Voicehovskis, Vladimirs
AU - Lejnieks, Aivars
AU - Kalējs, Oskars
PY - 2021/3/24
Y1 - 2021/3/24
N2 - Atrial fibrillations (AF), the most common sustained rhythm disorders, prevalence rises with the aging society. Although atrial fibrillation has been researched widely, the field of health-related quality of life (HRQoL) has become just recently more investigated. The aim of the study is to determine how different oral anticoagulant (OAC) usage influence the HRQoL for high-risk atrial fibrillation patients. High-risk non-valvular atrial fibrillation patients were enrolled during their hospitalization in Pauls Stradins Clinical University Hospital and Riga East University Hospital “Gailezers” year 2017 - 2020. Demographic data, medical history, therapy and modified SF-36 form were collected with a follow-up after 6- (6m) and 12 months (12m). Acquired data were analysed with Microsoft Excel and SPSS (Kruskall Wallis H-test). The 6-month follow-up included 213 patients; 12-month follow up - 186. Mean age 71.5 years. Mean CHA2DS2-VASc score 4.4. Study group: Non-OAC users 15.0% (32), Warfarin users 33.8% (72), NOAC users 51.1% (109). In warfarin group statistically significant difference (p<0.05) was identified in physical functioning (0m-0.41, 6m – 0.71, 12m – 0.63), emotional well-being (0m-0.73, 6m – 0.84, 12m – 0.76), social functioning (0m-0.72, 6m – 0.94, 12m – 0.89), general health (0m-0.33, 6m – 0.47, 12m – 0.46); in DOAC group physical functioning (0m-0.63, 6m – 0.65, 12m – 0.72), role limitations due to physical health problems (0m-0.51, 6m – 0.75, 12m – 0.73), social functioning (0m-0.79, 6m – 0.92, 12m – 0.97), general health (0m-0.37, 6m – 0.44, 12m – 0.51). In Non-user group a statistically significant negative change was in general health (0m-0.52, 6m – 0.43, 12m – 0.39) evaluation. Statistically significant (p<0.05) positive changes in health-related quality of life were determined in warfarin and DOAC user group. Non-user HRQoL during 12-month period had a negative correlation of health-related quality of life in 1 of 7 sections.
AB - Atrial fibrillations (AF), the most common sustained rhythm disorders, prevalence rises with the aging society. Although atrial fibrillation has been researched widely, the field of health-related quality of life (HRQoL) has become just recently more investigated. The aim of the study is to determine how different oral anticoagulant (OAC) usage influence the HRQoL for high-risk atrial fibrillation patients. High-risk non-valvular atrial fibrillation patients were enrolled during their hospitalization in Pauls Stradins Clinical University Hospital and Riga East University Hospital “Gailezers” year 2017 - 2020. Demographic data, medical history, therapy and modified SF-36 form were collected with a follow-up after 6- (6m) and 12 months (12m). Acquired data were analysed with Microsoft Excel and SPSS (Kruskall Wallis H-test). The 6-month follow-up included 213 patients; 12-month follow up - 186. Mean age 71.5 years. Mean CHA2DS2-VASc score 4.4. Study group: Non-OAC users 15.0% (32), Warfarin users 33.8% (72), NOAC users 51.1% (109). In warfarin group statistically significant difference (p<0.05) was identified in physical functioning (0m-0.41, 6m – 0.71, 12m – 0.63), emotional well-being (0m-0.73, 6m – 0.84, 12m – 0.76), social functioning (0m-0.72, 6m – 0.94, 12m – 0.89), general health (0m-0.33, 6m – 0.47, 12m – 0.46); in DOAC group physical functioning (0m-0.63, 6m – 0.65, 12m – 0.72), role limitations due to physical health problems (0m-0.51, 6m – 0.75, 12m – 0.73), social functioning (0m-0.79, 6m – 0.92, 12m – 0.97), general health (0m-0.37, 6m – 0.44, 12m – 0.51). In Non-user group a statistically significant negative change was in general health (0m-0.52, 6m – 0.43, 12m – 0.39) evaluation. Statistically significant (p<0.05) positive changes in health-related quality of life were determined in warfarin and DOAC user group. Non-user HRQoL during 12-month period had a negative correlation of health-related quality of life in 1 of 7 sections.
M3 - Abstract
SP - 125
T2 - RSU Research week 2021: Knowledge for Use in Practice
Y2 - 24 March 2021 through 26 March 2021
ER -